<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="utf-8">
    <title>Submission 613 from Anon (session_user_id: 9f2f80c594ca3e050c173abcf1e3787ccab1f4be)</title>
    <link href="../../../export.css" rel="stylesheet">
  </head>
  <body>
    <h1>Submission 613 from Anon (session_user_id: 9f2f80c594ca3e050c173abcf1e3787ccab1f4be)</h1>
    <div class="field-name" id="10aa9d89e69a5f7a">Q4. Dr Stephen Baylin speculates in the Economist article that "epigenetic
drugs altered the tumour cells in some lasting way that made them more
susceptible to standard chemotherapy." How can drugs that alter DNA methylation
have effects that last beyond the period of drug treatment? Discuss whether
there are any periods of development when you would avoid treating patients
with such drugs. In your answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe how altering DNA methylation can have enduring effects on the
        epigenome.
        <br>
    </li>
    <li>Define what is meant by a sensitive period.
        <br>
    </li>
    <li>Identify sensitive periods of development.
        <br>
    </li>
    <li>Explain why treating patients during sensitive periods would be inadvisable.
    <br>
</li>
</ul></div>
    <div class="field-value"><ul><li>
<p><span><span style="font-family:'Arial Black';">Describe how altering DNA methylation can have enduring effects on the epigenome. </span></span></p>
       <span><span style="font-family:Arial, sans-serif;">As we saw, DNA methylation is mitotically heritable and can alter permanently the expression of genes and the structure of chromatin.</span></span><br />       </li>
<li>
<p><span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Define what is meant by a sensitive period.</span></span></span></p>
     <span><span style="font-family:Arial, sans-serif;">We define as a sensitive period a time period when the environment may be able to influence epigenetic makeup.</span></span><br /><br /></li>
<li>
<p> <span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Identify sensitive periods of development.</span></span></span></p>
<p>     <span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span>We can identify three such sensitive periods: </span></span></span>        </p>
<p>        <span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span>1) The preimplantation period.</span></span></span></p>
<p>        <span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span>2) The early post implantation period.</span></span></span></p>
<p>        <span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span>3) Τhe period of primordial germ cell development all the way through to the production of mature eggs and sperms (gametogenesis).</span></span></span></p>
<p>        <span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span>These periods are periods of active remodelling of the epigenome, when marks are established rather than maintained.</span></span></span></p>
</li>
</ul><ul><li>
<p>    <span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Explain why treating patients during sensitive periods would be inadvisable. </span></span></span></p>
<p style="text-align:justify;">   <span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span>When we are treating young patients using drugs that cause epigenetic alterations, we have to consider the effects on germ cells because during gametogenesis these cells are in sensitive period of active remodelling of the epigenome. Any changes that wiil occur will pass to the next generations.</span></span></span></p>
</li>
</ul></div>

    <div class="field-name" id="961ab4c640df430a">Q3. The Economist article “<a href="http://www.economist.com/node/21552168" target="_blank">Cancer’s epicentre</a>” describes several drugs that affect
    epigenetic processes. Explain how Decitabine may be used to treat cancer,
    with reference to effects on the epigenome. In your answer include the
    following points:
<br>
<p></p>
    <ul>
        <li>Identify the class of epigenetic inhibitors that Decitabine belongs to.&nbsp;
            <br>
        </li>
        <li>Describe the impact of Decitabine on DNA methylation.
            <br>
        </li>
        <li>Describe how Decitabine can have an anti-tumour effect.&nbsp;
            <br>
        </li>
    </ul></div>
    <div class="field-value"><ul><li>
<p> <span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Identify the class of epigenetic inhibitors that Decitabine belongs to.</span></span></span></p>
</li>
</ul><p>       Decitabine or 5-aza-2'-deoxycytidine (trade name Dacogen) is a DNA MethylTransferase (DNMT) inhibitor. Chemically, it is a nuceloside (cytidine) analog.</p>
<p> </p>
<ul><li>
<p> <span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Describe the impact of Decitabine on DNA methylation. </span></span></span></p>
<p>Decitabine hypomethylates DNA by inhibiting DNA methyltransferase. Nucleoside analogues, like decitabine, irreversibly bind DNMT after they have been incorporated into DNA. Therefore their action is dependent on DNA replication.</p>
<p>      </p>
</li>
</ul><ul><li>
<p><span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Describe how Decitabine can have an anti-tumour effect.  </span></span></span></p>
<p>The exact mechanism of action is still unclear. Decitabine appears to affect genes that control cell growth by inhibiting DNMTs (after it has been incorporated into DNA) and activating tumour suppressor genes that have been inactivated previously by hypermethylation. Being a nucleoside analogue, is also thought to act as an anti-metabolite having a non-specifc toxic effect on cells. The abnormal cells, which divide more frequently, are affected in greater degree.</p>
</li>
</ul></div>

    <div class="field-name" id="d6002606a5ec3d03">Q1. Describe how DNA methylation is altered in cancer.
In your answer include the following points:
<br><p></p><ul><li>Describe the normal
function of DNA methylation at CpG islands.<br></li><li>Describe how DNA
methylation of CpG islands is disrupted in cancer.<br></li><li>Explain how disruption of
DNA methylation at CpG islands contributes to cancer.<br></li><li>Describe the normal
function of DNA methylation in intergenic regions and repetitive elements.<br></li><li>Describe how DNA
methylation in intergenic regions and repetitive elements is disrupted in cancer.<br></li><li>Explain how disruption
of DNA methylation in intergenic regions and repetitive elements contributes to
cancer.<br></li></ul><p></p></div>
    <div class="field-value"><ul><li>
<p><span><span style="font-family:'Arial Black';">Describe the normal function of DNA methylation at CpG islands.</span></span></p>
</li>
</ul><p><span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span><span>Generally, DNA Methylation at CpG island</span><span>s</span><span> of promoter regions inversely correlates with gene expression. </span>DNA methylation in a CpG island is also associated with the formation of a repressive chromatin structure (<span style="color:#000000;"><span>heterochromatin</span></span><span style="color:#000000;"><span>)</span></span>. <span style="color:#000000;"><span>Inactive X chromosome shows DNA methylation of CpG islands</span></span><span style="color:#000000;"><span>. </span></span></span></span></span></p>
<p><span style="color:#333333;"><span style="font-family:Arial, sans-serif;"><span><span style="color:#000000;"><span><br /></span></span></span></span></span></p>
<ul><li>
<p><span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Describe how DNA methylation of CpG islands is disrupted in cancer.</span></span></span></p>
</li>
</ul><p>In cancer cells, promoter CpG islands tend to become hypermethylated, which then causes silencing of the underlying genes (e.g. tumour suppressor genes). CpG island hypermethylation occurs frequently in tumours because DNA methylation is mitotically heritable and epimutations are rapidly selected. The exact identity of hypermethylated CGIs varies by tumour type.</p>
<p> </p>
<ul><li>
<p><span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Explain how disruption of DNA methylation at CpG islands contributes to disease.</span></span></span></p>
<p><span><span style="font-family:Arial, sans-serif;">DNA methylation at CpG islands contributes to disease by silencing e.g. tumour suppressor genes.</span></span><span style="line-height:21px;font-size:14px;">     </span></p>
<p><span style="line-height:21px;font-size:14px;"> </span></p>
</li>
</ul><ul><li><span><span style="font-family:'Arial Black';">Describe the normal function of DNA methylation in intergenic regions and repetitive elements.</span></span>  </li>
</ul><ul><li><span style="line-height:21px;font-size:14px;">Maintain genomic integrity:</span></li>
</ul><ol><li><span><span>  Silencing of genes</span></span></li>
<li><span><span>  Silencing of repeats to prevent transposition.</span></span></li>
<li>  Mutation of the repeats (meC to T) to prevent transposition.</li>
<li><span><span>  Silencing of repeats, so avoid transcriptional interference from strong promoters.</span></span></li>
<li> <span> M<span>ethylation of repeats may prevent illegitimate recombination.</span></span></li>
</ol><p>       </p>
<ul><li>
<p> <span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Describe how DNA methylation in intergenic regions and repetitive elements is disrupted in cancer.</span></span></span></p>
<p>        <span style="color:#333333;"><span style="font-family:'Helvetica Neue', Helvetica, Arial, sans-serif;"><span>Ιn cancer, frequently, the earliest epigenetic aberration found is a genome-wide lack of methylation. We can see DNA </span></span></span><span><span>hypomethylation of intergenic regions, repeats, CpG poor promoters and <span>ICRs.</span></span></span></p>
<p><span><span><span><br /></span></span></span></p>
</li>
</ul><ul><li>
<p> <span style="color:#333333;"><span style="font-family:'Arial Black';"><span>Explain  how disruption of DNA methylation in intergenic regions and repetitive elements contributes to disease.</span></span></span></p>
 <span><span style="font-family:Arial, sans-serif;"><span style="font-size:small;">Genomic Instability.</span></span></span></li>
</ul><p><span><span style="font-family:Arial, sans-serif;"><span style="font-size:small;">        Illegitimate recombination between repeats.</span></span></span>    </p>
<p>       <span><span style="font-family:Arial, sans-serif;"><span style="font-size:small;"> Activation of repeats and transposition.</span></span></span></p>
<p>        <span><span style="font-family:Arial, sans-serif;"><span style="font-size:small;">Activation of cryptic promoters and disruption to neighbouring genes.</span></span></span></p>
<p>        <span><span><span style="font-size:small;">Hypomethylation of CpG poor promoters (</span></span></span><span><span style="font-family:Arial, sans-serif;"><span style="font-size:small;">activation of genes e.g. ongogenes).</span></span></span></p></div>

    <div class="field-name" id="323cdd9789545f83">Q2. Describe how disruption of imprinting can contribute to cancer, using the example of the H19/Igf2 cluster. In your
answer include the following points:
<br>
<p></p>
<ul>
    <li>Describe the methylation pattern of the paternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe the methylation pattern of the maternal allele and how this determines
        Igf2 expression status.&nbsp;
        <br>
    </li>
    <li>Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm’s tumour.&nbsp;
        <br>
    </li>
    <li>Explain how disrupting imprinting at the H19/Igf2 cluster contributes to cancer.
        <br>
    </li>
</ul></div>
    <div class="field-value"><p><br /><img src="https://coursera-uploads.s3.amazonaws.com/user-4502f2c1128ede80bb82c394/970238/asst-5/970238-520a67304b6792.54667450.png" alt="" /></p>
<p>  <span><span style="font-family:'Arial Black';">Describe the methylation pattern of the paternal allele and how this determines Igf2 expression.</span></span></p>
<p>The ICR (Imprinted Control Region) is methylated on the paternal allele. The insulator protein CTCF cannot bind to ICR. If CTCF isn't binding, there is no insulator action and the enhancers are free to act on Igf2 and promote Igf2's expression from the paternal allele.</p>
<p><span style="font-family:'Arial Black';">Describe the methylation pattern of the maternal allele and how this determines Igf2 expression. </span></p>
<p>The ICR is unmethylated on the maternal allele and it is bound by an insulator protein called CTCF that insulates Igf2 from the downstream enhancers. Therefeore, Igf2 is not expressed from the maternal allele.</p>
<p><span style="font-family:'Arial Black';">Describe how imprinting at the H19/Igf2 cluster is disrupted in Wilm's tumour.</span></p>
<p><span style="text-align:justify;">We have loss of the maternal like allele or both alleles behaving like the paternal allele. We may have loss of imprinting or uniparental disomy.</span></p>
<p><span><span style="font-family:'Arial Black';">Explain how disrupting imprinting at the H19/Igf2 cluster contributes to disease.</span></span></p>
<p style="text-align:justify;">Alterations in DNA methylation at ICRs, can result in loss of expression of growth restricting genes or overexpression of growth promoting genes. In the case of Wilm's tumour we may have hypermethylation of maternal ICR and overexpression of Igf2.</p></div>
  </body>
</html>